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Main text 
A recently published systematicreview on the treatment of chronic hepatitis C (CHC) with direct-acting antivirals 
(DAAs) performed by the Cochrane’s Collaboration has reached highly controversial conclusions. [1-2] The 
authors selected included 138 randomized controlled trials (RCT) with no restriction on patients’ stage of disease 
and the type of DAA combinations. They concluded that there was no evidence either to confirm or to reject the 
premise that DAAs had any clinical effects and they also stated that sustained virological response (SVR) was an 
unreliable surrogate marker to assess clinical efficacy. We would like to differ on both these counts. Their results 
are in discordance with current international guidelines [3-4] the opinion of the of scientific societies for the study 
of liver diseases in Europe [5] and in America [6] and the endorsement of the World Health Organization (WHO) 
which state that DAAs can eliminate HCV by 2030 [7-9]. These results reflect an underestimation of the actual 
value of observational evidence in the context of the current knowledge of CHC clinical management. [10-11] 
Current knowledge on CHC 
First identified in 1989 [12] Hepatitis C virus (HCV) was associated with severe degenerative processes affecting 
different tissues and organs including liver damage, metabolism imbalance, immunological deregulation and 
increased risk of cancer. [13] Studies on the natural history of CHC established that about 15%-20% of subjects 
exposed to HCV die as a direct consequence of the infection. Therapy against CHC in the ‘90s involved using a 
host targeted therapy with alpha interferon plus ribavirin (a weak antiviral compound). DAAs were introduced in 
2014. Evidence from clinical studies has demonstrated that DAA combinations have extraordinary efficacy and 
safety with rate of resolution of infection ranging between 80-100%. [14-18] 
SVR (i.e. undetectable HCV RNA over a certain period of time) has been always considered the best surrogate 
marker for natural and drug induced resolution of HCV infection. Meta-analyses performed on recent RCTs and 
non-randomized studies have provided strong evidence that patients with SVR experienced significantly lower 
morbidity and mortality than viremic ones [19-21]. An example of the potential impact of SVR on patients’ health 
is reported in Figure 1 which shows an original overview on five meta-analyses comparing the risk of 
hepatocellular carcinoma in patients who either did or did not achieve SVR. Overall this analysis suggests that 
SVR reduce the risk of HCC by 3 to 5 times. 
Limitation 
The main limitation of the Cochrane review is that its study design, thought formally impeccable, was not tailored 
to answer the critical clinical questions on CHC management. There are several drawbacks of the study.  
Firstly, the study lacks a clinically oriented restriction framework for defining whichstudy population(s) and which 
intervention(s) are under assessment. [22] Restriction is a strategy commonly employed for controlling 
confounding bias at the study design by the selection of a homogeneous study sample and comparable 
interventions, so that study results are solid within the defined set of assumptions. It is noteworthy that controlling 
confounding bias at study design level is pivotal in meta-analyses of aggregated data which can hardly manage 
confounding at the level of analysis (ecological fallacy). [23] The Cochrane review polled results from studies 
including subjects with radically different clinical background and receiving heterogeneous combinations of 
DAAs (and interferon). Therapies with DAA can never be considered as a unique intervention. Instead, there is 
solid evidence that DAAs should be used in specific combinations and defined posology according to diseases 
stage, exposure to previous treatments, HCV genotype and viral profile of resistance.[2-3] Ignoring that, several 
combinations of DAA which have been marketed since 2014, are currently considered either sub-optimal (e.g. 
those including only one DAA) or too toxic (e.g. those including first and second generation DAA plus interferon) 
[24] may produce results that are inconsistent with the real word clinical practice. In particular, 57 out of 138 
RCTs (41%) included in the Cochrane review were studies carried out on DAAs which were never marketed or 
have already been withdrawn. Moreover, even the analysis to assess efficacy (i.e. SVR) carried out with 33 RCTs 
including only experimental or approved DAAs can hardly inform clinical decisions. In fact, most of these 33 
RCTs had an experimental arm consisting in a single DAA in addition to interferon and ribavirin (currently not 
recommended). Overall only 3 out of 33 RCTs included in this analysis assessed interferon-free DAA 
combinations and only 2 of those included an experimental arm consisting in a currently recommend DAA 
combination.  
Secondly, while inclusion criteria based on patients’ clinical features and type of interventions were exceedingly 
wide, criteria for selection of the studies according to design were remarkably strict and only explanatory RCTs, 
[25] with a control group receiving no DAA, were included. This decision resulted in the exclusion of pivotal 
information from large phase III trials (including DAAs in parallel arms) and non-randomized studies that 
resemble current use of DAAs much better than the included RCTs. [26] Even if non-randomized studies fail now 
and then in prediction of the real effects of new medical interventions, evidence from observational studies may 
be as credible as those from RCTs to assess unintended events, such as adverse drug reactions. [27] In addition, it 
is well expected that a set of explanatory RCTs with short follow-up and not entirely focused on patients with 
cirrhosis would have been severely underpowered to assess sequalae of HCV infections that characterize the final 
stage of CHC; such as liver morbidity and reduction of life quality. [10]  
Finally, the Cochrane review appears to assume that SVR, which has been used for the last 25 years as the main 
surrogate marker to assess the success of anti-HCV therapy, is fundamentally unreliable as it has never been 
validated in a formal RCT. This implies that one should also repeal all the current knowledge about clinical 
management of CHC. In our opinion, the notion that robust enough evidence to guide clinical decisions can only 
come from RCTs, is based on two crucial misconceptions. Firstly, the idea that randomization is always feasible, 
which if false as the ethical basis of RCTs [28] relies on the principle of clinical equipoise (i.e. lack of evidence 
that the experimental treatment is better than the standard of care) and individual uncertainty (i.e. investigators 
and patients are uncertain about the merits of the experimental treatment). With regard to CHC, the time of 
equipoise and uncertainty has well expired since the time of dual therapy with interferon and ribavirin. Thus, 
randomizing patients for no therapy, to study the effect of SVR on the evolution of CHC (i.e. the natural history) 
is rather unethical both in term of the risk for the individual patients (who will progress towards end stage liver 
diseases) and the risk for the community (achieving SVR reduces the infectivity and is crucial step for HCV 
elimination). [6,29-30] Secondly, the misconception that observational studies are an alternative to 
experimentation rather than a set of complementary approaches. Observational studies served to investigate non-
randomizable conditions and, in fact, interpret correctly the results obtained from RCTs themselves. [18,31] 
Merits and perspective 
Despite these drawbacks the Cochrane review has several merits. It highlights that DAAs are not the miracle drugs 
that has been publicly perceived. [7] To prove or disprove this, there is a need to measure the real impact of DAAs 
both on patients and community welfare.  
DAAs are radically innovative compounds. In contrast to interferon based therapy which exert their effect by 
targeting host cells, [32] DAAs have no effects on host, including those (desirable) on liver fibrosis modulation 
[33] and enhancement of cellular immunity against cancer. [34] Thus, the questions on whether and how much 
SVR obtained by DAAs translates into recovery from liver damage, systemic abnormalities and finally improve 
patients’ quality of life is legitimate. Indeed, recent observational studies emphasizes that ALT (a marker of liver 
cytolysis) normalize in most but not all patients who achieve SVR with DAAs, suggesting that clearance of 
infection does not always revert damage at cellular level. [35] In addition, from a public heath point of view it is 
pivotal to define the effectiveness (i.e. the general impact) of an extended use of DAAs with the aim of the 
elimination of HCV. [4] In particular, pros and cons of extended use of molecular testing and expensive therapy 
with DAAs should be tailored on availability of local resources, patterns of risk for re-infections in special 
populations and the topical needs of the local communities.  
We suggest that future research on CHC should take forward the implementation of high quality quantitative 
studies to measure how SVR translate into health improvement. These studies need solid and measurable clinical 
endpoints to assess recovery form CHC associated conditions which may significantly impact on patient’s life 
quality and expectancy; such as: recovery form metabolic imbalance (e.g. insulin resistance), reduction of liver 
damage (e.g. fibrosis) and improvement of liver function in patients who achieved SVR when cirrhosis was already 
established. In addition, large population studies are also needed to assess the impact of DAAs on reduction of late 
CHC sequalae and to explore the potential of DAAs for HCV eradication at a global level. 
Conclusion 
The results of Cochrane review can hardly inform current clinical decisions. In fact, the systematic review and 
meta-analyses are mainly based on CHC treatments which are no longer recommend and on outcomes that cannot 
be assessed by explanatory RCTs with short follow-ups. At present there is a need to build up reliable models for 
making more accurate predictions about patient’s prognosis and the efficacy of novel treatments and prevention 
interventions.  
RCTs may be practically unfeasible to assess the effect of new DAAs on long term outcomes such as the reduction 
of the overall mortality and the recovery for extra-hepatic conditions in patients with CHC at an early clinical 
stage. In these circumstances medical science should be capable of judging quality and take advantage from 
observational evidence and building on preexisting knowledge. Since currently recommended DAA combinations 
have already proved to have extraordinary efficacy in obtaining SVR, future studies should be aimed to assess 
whether SVR: A) coincides with the eradication of HCV infection; B) improves life expectancy; C) can stop, or 
even revert, hepatic damage; D) is associated with the improvement extra-hepatic conditions related to CHC. Long 
lasting observational cohort studies are, in our opinion, the best way to assess all these issues.  
Moreover, from a public health point of view, there is a need for the implementation of population studies aimed 
to assess the risk of re-infection and the capability to effectively reach special populations. In fact, as a vaccine is 
not available, the results of public health programmes aimed to eliminate HCV infection at national and 
supranational level will mainly depend on the capability to identify social niches of HCV transmission, to provide 
treatment to difficult-to-reach people and to prevent the risk of reinfection in people with high risk behaviors. In 
these setting large population studies and, potentially, well-designed population trials such as those implemented 
for the prevention of HIV (e.g. cluster randomized trials) [36] may be necessary.  
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Figure 1. Meta-analyses overview. We searched Pubmed for meta-analyses which: A) directly assess the effect of 
SVR on the risk of hepatocellular carcinoma; B) included 3 studies or more; C)were published over the last 15 
years (i.e. since January 2003). In this way we found 5 large meta-analyses including a total of 45 individual 
studies (2 RCT, 12 prospective cohorts and 31 historical studies; each study can be included in more than one 
meta-analysis). The figure reports information of 45,428 cases of CHC (20,891 with SVR and 24,537 without 
SVR) at different stage of liver diseases and different exposure to interferon and ribavirin. Overall the analysis 
suggests that SVR reduce the risk of HCC by 3 to 5 times. Heterogeneity was low and due to a unique study. N. 
Studies indicates the number of studies included in each meta-analysis. 
 
Methodological note. The string used for the search was: (("Hepatitis C"[Mesh] OR "Hepatitis C, Chronic"[Mesh]) 
AND "Carcinoma, Hepatocellular"[Mesh]) AND "Meta-Analysis"[Publication Type] AND 
("2003/01/01"[PDAT] : "2017/12/01"[PDAT])]. 
We reviewed 46 studies. We excluded 41 studies: 29 focused on condition different from SVR in CHC; 6 focused 
on HCC recurrence; 4 evaluated adjuvant therapies for HCC; 1 because included only 2 studies and 1 because it 
was published in Chinese only. We did not provide a unique estimate of polled effect as a single study may be 
included in more than one meta-analysis 
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